ReviewInternational journal of molecular sciences2022
Irisin and Secondary Osteoporosis in Humans.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Protective role of irisin on bone in osteoporosis: a systematic review of rodent studies.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025Pooled it
- Variations and implications of Irisin, FGF-23, and N-MID osteocalcin in diabetic osteoporosis patients undergoing acarbose plus sitagliptin therapy: A prospective cohort analysis.Journal of medical biochemistry · 2026Article
- Myokine Levels in Relation to Bone Markers and Adipokines in Children with Prader-Willi Syndrome During Growth Hormone Therapy and Dietary Intervention.International journal of molecular sciences · 2025Article
- The Effects of Irisin and Bevacizumab on Hyaline Cartilage Regeneration in Osteochondral Defects: An Experimental Study in Rats.Clinics in orthopedic surgery · 2025Article
- Irisin mitigates osteoporotic-associated bone loss and gut dysbiosis in ovariectomized mice by modulating microbiota, metabolites, and intestinal barrier integrity.BMC musculoskeletal disorders · 2025Article
- Irisin and its role in fracture healing: A comparative study with hyaluronic acid and platelet-rich plasma in a rat model.Joint diseases and related surgery · 2025Article
- Irisin Protects Musculoskeletal Homeostasis via a Mitochondrial Quality Control Mechanism.International journal of molecular sciences · 2024Review
- New insights into the vitamin D/PTH axis in endocrine-driven metabolic bone diseases.Endocrine · 2024Review
- Irisin promotes hair growth and hair cycle transition by activating the GSK-3β/β-catenin pathway.Experimental dermatology · 2024Article
- The therapeutic potential of irisin to mitigate the risk of metabolic syndrome in postmenopausal women.Frontiers in reproductive health · 2024Review
- Molecular origin and biological effects of exercise mimetics.Journal of exercise science and fitness · 2024Review
- A 21-Day Individual Rehabilitation Exercise Training Program Changes Irisin, Chemerin, and BDNF Levels in Patients after Hip or Knee Replacement Surgery.Journal of clinical medicine · 2023Article
- Serum irisin levels and osteoporosis in patients with advanced chronic kidney disease and renal transplant recipients.International urology and nephrology · 2023Article
- Unlocking the Therapeutic Potential of Irisin: Harnessing Its Function in Degenerative Disorders and Tissue Regeneration.International journal of molecular sciences · 2023Review
- Vitamin D Increases Irisin Serum Levels and the Expression of Its Precursor in Skeletal Muscle.International journal of molecular sciences · 2023Article
- Recombinant irisin prevents cell death and mineralization defects induced by random positioning machine exposure in primary cultures of human osteoblasts: A promising strategy for the osteoporosis treatment.Frontiers in physiology · 2023Article
- Irisin: An anti-inflammatory exerkine in aging and redox-mediated comorbidities.Frontiers in endocrinology · 2023Review
- Irisin and Bone in Sickness and in Health: A Narrative Review of the Literature.Journal of clinical medicine · 2022Review
- Exercise and Exercise Mimetics for the Treatment of Musculoskeletal Disorders.Current osteoporosis reports · 2022Review
- Regulated necrosis, a proinflammatory cell death, potentially counteracts pathogenic infections.Cell death & disease · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Irisin is a peptide secreted by skeletal muscle following exercise that plays an important role in bone metabolism. Numerous experiments in vitro and in mouse models have shown that the administration of recombinant irisin promotes osteogenesis, protects osteocytes from dexamethasone-induced apoptosis, prevents disuse-induced loss of bone and muscle mass, and accelerates fracture healing. Although some aspects still need to be elucidated, such as the dose- and frequency-dependent effects of irisin in cell cultures and mouse models, ample clinical evidence is emerging to support its physiological relevance on bone in humans. A reduction in serum irisin levels, associated with an increased risk of osteoporosis and bone fractures, was observed in postmenopausal women and in both men and women during aging, Recently, cohort studies of subjects with secondary osteoporosis showed that these patients have lower circulating levels of irisin, suggesting that this myokine could be a novel marker to monitor bone quality in this disease. Although there are still few studies, this review discusses the emerging data that are highlighting the involvement of irisin in some diseases that cause secondary osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.